GSK upbeat on meningitis vaccine candidate, asthma treatment
14th Mar 2023 09:35
(Sharecast News) - Pharmaceutical giant GSK reported positive results from a phase three trial evaluating its MenABCWY combination vaccine candidate for meningitis on Tuesday.
Read moreGSK's ViiV says trial indicates HIV shot as effective as rival Gilead pill
23rd Feb 2023 08:11
(Sharecast News) - UK pharma firm GSK's HIV treatment division, ViiV Healthcare, said its HIV injection treatment was as effective as a daily pill made by Gilead Sciences.
Read moreBerenberg raises target price on GSK
10th Feb 2023 08:29
(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker GSK from £15.80 each to £17.30 on Friday, citing "steady progress".
Read moreGSK's endometrial cancer treatment receives full FDA approval
10th Feb 2023 07:07
(Sharecast News) - Drugmaker GSK's mismatch repair-deficient recurrent or advanced endometrial cancer treatment has been granted full approval by the Food and Drug Administration.
Read moreFDA approves GSK anaemia drug
2nd Feb 2023 08:19
(Sharecast News) - The US regulator has given the green light to a GSK treatment for anaemia in patients with chronic kidney disease, the medicines and vaccines group confirmed on Thursday.
Read moreRecord vaccine sales boost profits at GSK
1st Feb 2023 07:18
(Sharecast News) - Fourth-quarter profits at GSK came in ahead of expectations on Wednesday, boosted by strong demand for the drug giant's blockbuster shingles vaccine.
Read moreGSK plans return of HQ to central London in 2024
12th Dec 2022 14:18
(Sharecast News) - GSK on Monday said it was moving its global headquarters back to central London in 2024.
Read moreGSK shares jump as court dismisses ranitidine claims
7th Dec 2022 07:29
(Sharecast News) - GSK shares were surging on Wednesday morning, as it welcomed a ruling by the multi-district litigation court (MDL) over the heartburn drug ranitidine on Wednesday.
Read moreGSK cancer treatment meets trial endpoint
2nd Dec 2022 07:39
(Sharecast News) - GSK on Friday unveiled positive headline results from a Phase 3 trial of its Jemperli endometrial cancer drug.
Read moreEU validates market application for blood cancer drug
2nd Dec 2022 07:03
(Sharecast News) - GSK said the European Medicines Agency had validated its marketing authorisation application for momelotinib, a potential new oral treatment for the blood cancer myelofibrosis after meeting key endpoints in a Phase 3 trial.
Read moreShoreCap stays at 'buy' for GSK, points to significant discount versus peers
22nd Nov 2022 11:39
(Sharecast News) - Analysts at ShoreCap reiterated their 'buy' recommendation for shares of GSK despite news that its Blenrep treatment against multiple myeloma was set to be withdrawn from the US Market.
Read moreGSK starts moves to pull FDA approval for blood cancer drug
22nd Nov 2022 08:00
(Sharecast News) - British pharmaceutical giant GSK on Tuesday said it has started proceedings to pull US approval for its blood cancer drug Blenrep after it failed to meet the requirements of a late-stage trial.
Read moreSecond-line use of GSK cancer drug restricted
11th Nov 2022 07:28
(Sharecast News) - The second-line application of a GSK cancer treatment will be limited following a request by the US regulators, the drugs giant said on Friday.
Read moreGSK's Blenrep fails to meet primary endpoint in phase III trial
7th Nov 2022 08:08
(Sharecast News) - Drugmaker GSK said on Monday that its relapsed or refractory multiple myeloma drug candidate, Blenrep, had failed to meet its primary endpoint of progression-free survival in a recent phase III trial.
Read moreGSK halts antibiotic trials early
3rd Nov 2022 07:52
(Sharecast News) - GSK has halted patient enrolment in trials for a novel antibiotic, the drug and vaccine giant said on Thursday.
Read more